Home/Recalls/FDA-D-0380-2026
FDA DrugsClass II

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; ...

Published: March 11, 2026Recall ID: D-0380-2026Category: drugsCountry: US

Reason for Recall / Hazard

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Product Description & Identification

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China.

Affected Products

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China.

Additional Source Details

FieldValue
CityHaerbin
StateN/A
Event id98438
Address 1North Of Baoan Road, East Of Changqing Street
Address 2Hulan District
Code infoBatch # CP-030-20250911, Mfg Date: Sep. 25th, 2025, Retest Date: Sep. 24th, 2027.
Postal codeN/A
Report date20260311
Product typeDrugs
Product quantityN/A
Reason for recallCGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
Voluntary mandatedVoluntary: Firm initiated
Recall initiation date20260213
Initial firm notificationE-Mail
Center classification date20260302

Overview

  • Recalling FirmHarbin Jixianglong Biotech Co., Ltd.
  • StatusOngoing
  • Risk LevelClass II
  • DistributionNationwide within the United States
Official Agency Alert